Premenopausal women presenting with acute coronary syndrome (ACS) are a unique and often underrecognized patient population. Although they are traditionally considered at lower cardiovascular risk ...
Total net revenue of $15.2 million Adjusted EBITDA1 of $ (0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) ...
Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-r ...
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel ...
Objectives Female sex and anticitrullinated protein antibodies (ACPA) are associated with higher disease activity in ...